

Anti-CD4 (Clenoliximab), Human IgG4 Antibody

CATALOG NO:	A1091-200
ALTERNATIVE NAMES:	p55; T cell surface antigen T4/Leu-3
AMOUNT:	200 µg
IMMUNOGEN:	Domain 1 of human CD4
ISOTYPE / FORMAT:	Human IgG4, lambda
CLONALITY:	Monoclonal
CLONE:	CE9.1
SPECIES REACTIVITY:	Human, chimpanzee
FORM:	Liquid
SPECIFICITY:	The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 µg/ml.
PURIFICATION:	Affinity purified using Protein A
FORMULATION:	Supplied in PBS with preservative (0.02% Proclin 300)
STORAGE CONDITIONS:	Store at 4°C for upto 3 months. For long term storage, aliquot and freeze at -20°C. Avoid repeated freeze/thaw cycles.
DESCRIPTION:	Recombinant monoclonal antibody to CD4. Manufactured using recombinant technology with variable regions (i.e. specificity) from the hybridoma CE9.1 (Clenoliximab). This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques.
BACKGROUND:	The antibody binds specifically to CD4, a molecule which is part of the immunoglobulin super-family, expressed on the surface of helper T cells. The CD4 molecule acts as a co-receptor in the activation of T cells, aiding the interaction between the TCR and MHC II of the antigen-presenting cell. The antibody is classified as "primatized", as the variable regions of the light and heavy chains are obtained from primates, while the lambda light chain and gamma4 heavy chain constant domains are human. The antibody was engineered from the primatized IgG1 monoclonal antibody Keliximab by substituting two key residues. The role of the antibody as an immunosuppressor has been tested in vivo, by intravenous administration in chimpanzees and human volunteers. The antibody reached Phase II clinical trials with Biogen-Idex.
APPLICATION:	ELISA; FC; Block; SPR; IHC

REFERENCE: Newman *et al.* Primatization of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. *Biotechnology (NY)*. 1992 Nov; 10 (11):1455-60.

RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), humanized Antibody (**Cat. No. A1045-100**)
- Anti-HER2 (Trastuzumab), humanized Antibody (**Cat. No. A1046-100**)
- Anti-EGFR (Cetuximab), Chimeric Antibody (**Cat. No. A1047-100**)
- Anti-TNF-α (Adalimumab), humanized Antibody (**Cat. No. A1048-100**)
- Anti-CD20 (Rituximab), Chimeric Antibody (**Cat. No. A1049-100**)
- Anti-EGFR (Panitumumab), humanized antibody (**Cat. No. A1050-100**)
- Anti-OX40L (Oxelumab), Human IgG1 Antibody (**Cat. No. A1088-200**)
- Anti-CD11a (Efalizumab), Human IgG1 Antibody (**Cat. No. A1089-200**)
- Anti-EGFR (Matuzumab), Human IgG1 Antibody (**Cat. No. A1090-200**)
- Anti-alpha 5 beta1 Integrin (Volociximab), Human IgG4 Antibody (**Cat. No. A1092-200**)
- Anti-TNF alpha (Humicade), Human IgG4 Antibody (**Cat. No. A1093-200**)
- Anti-CD40L (Ruplizumab), Human IgG1 Antibody (**Cat. No. A1094-200**)
- Anti-Human Ephrin Type A receptor 2 (1C1), Human IgG1 Antibody (**Cat. No. A1095-200**)
- Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody (**Cat. No. A1096-200**)
- Anti-TNF alpha (Infliximab), Human IgG1 Antibody (**Cat. No. A1097-200**)
- Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (**Cat. No. A1098-200**)
- Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody (**Cat. No. A1099-200**)

FOR RESEARCH USE ONLY! Not to be used on humans.

